Microvessel density and CPG island methylation of THBS2 gene in malignant ovarian tumors

Journal of Physiology and Pharmacology

Volumn 59, Issue SUPPL. 4, 2008, Pages 53-65

  Czekierdowski, Artur ^a   Czekierdowska, S ^a   Danilos, J ^a   Czuba, B ^b   Sodowski, K ^b   Sodowska, H ^b   Szymanski, M ^c   Kotarski, J ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b MEDICAL UNIVERSITY OF SILESIA   (Poland)

^c NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

CpG island methylation; Microvessel density; Ovarian cancer; THBS2 gene

Indexed keywords

CD34 ANTIBODY; MESSENGER RNA; THROMBOSPONDIN 2;

ARTICLE; CANCER GRADING; CANCER STAGING; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DOWN REGULATION; FEMALE; GENE; GENE EXPRESSION; GENE SILENCING; HUMAN; MAJOR CLINICAL STUDY; MICROVASCULATURE; OVARY CANCER; POLYMERASE CHAIN REACTION; PROMOTER REGION; THBS2 GENE;

ANTIGENS, CD34; CPG ISLANDS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; METHYLATION; MICROVESSELS; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; OVARY; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THROMBOSPONDINS;

EID: 53549129493     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Folkman J. Fundamental concepts of the angiogenic process. Curr Mol Med 2003; 3: 643-651.
2. Motyl T, Gajkowska B, Zarzyñska J, Gajewska M, Lamparska-Przybysz M. Apoptosis and autophagy in mammary gland remodeling and breast cancer chemotherapy. J Physiol Pharmacol 2006;57(Suppl 7):17-32.
3. Iruela-Arispe ML, Luque A, Lee N. Thrombospondin modules and angiogenesis. Int J Biochem Cell Biol 2004; 6: 1070-1078.
4. Kucia M, Ratajczak MZ. Stem cells as a two edged sword-from regeneration to tumor formation. J Physiol Pharmacol 2006; 57(Suppl 7): 5-16.
5. Nowak K, Hanusch C, Kölbel HC et al. Alterations of tumor and normal tissue of human lung cancer resection specimens after isolation perfusion. J Physiol Pharmacol 2007; 58(Suppl 5/2): 501-511.
6. Adams JC, Monk R, Taylor AL et al. Characterisation of Drosophila thrombospondin defines an early origin of pentameric thrombospondins. J Mol Biol. 2003; 328: 479-494.
7. Adams JC. Functions of the conserved thrombospondin carboxy-terminal cassette in cell-extracellular matrix interactions and signaling. Int J Biochem Cell Biol 2004; 36: 1102-1114.
8. Misenheimer TM, Mosher DF. Biophysical characterization of the signature domains of thrombospondin-4 and thrombospondin-2. J Biol Chem 2005; 280: 41229-41235.
9. Laherty CD, O'Rourke K, Wolf FW, Katz R, Seldin MF, Dixit VM. Characterization of mouse thrombospondin 2 sequence and expression during cell growth and development. J Biol Chem 1992; 267: 3274-3281.
10. Bornstein P, Sage EH. Thrombospondins. Methods Enzymol 1994; 245: 62-85.
11. Chen H, Sottile J, Strickland DK, Mosher DF. Binding and degradation of thrombospondin-1 mediated through heparan sulphate proteoglycans and low-density-lipoprotein receptor-related protein: localization of the functional activity to the trimeric N-terminal heparin-binding region of thrombospondin-1. Biochem J 1996; 318: 59-963.
12. Lawler J, Detmar M. Tumor progression: the effects of thrombospondin-1 and -2. Int J Biochem Cell Biol 2004; 36: 1038-1045.
13. Volpert OV, Tolsma SS, Pellerin S et al. Inhibition of angiogenesis by thrombospondin-2. Biochem Biophys Res Commun 1995; 217: 326-332.
14. Panetti TS, Chen H, Misenheimer TM, Getzler SB, Mosher DF. Endothelial cell mitogenesis induced by LPA: inhibition by thrombospondin-1 and thrombospondin-2. J Lab Clin Med 1997; 129: 208-216.
15. Bornstein P, Armstrong LC, Hankenson KD, Kyriakides TR, Yang Z. Thrombospondin 2, a matricellular protein with diverse functions. Matrix Biol 2000; 19: 557-568.
16. Pellerin S, Lafeuillade B, Chambaz EM, Feige JJ. Distinct effects of thrombospondin-1 and CISP/thrombospondin-2 on adrenocortical cell spreading. Mol Cell Endocrinol 1994; 106: 181-186.
17. Bornstein P, Agah A, Kyriakides TR. The role of thrombospondins 1 and 2 in the regulation of cell-matrix interactions, collagen fibril formation, and the response to injury. Int J Biochem Cell Biol 2004; 36: 1115-1125.
18. Pajak B, Orzechowski A. Sodium butyrate-dependent sensitization of human colon adenocarcinoma COLO 205 cells to TNF-alpha-induced apoptosis. J Physiol Pharmacol 2007; 58(Suppl 3):163-176.
19. Fontanini G, Boldrini L, Calcinai Aet al. Thrombospondins I and II messenger RNA expression in lung carcinoma: relationship with p53 alterations, angiogenic growth factors, and vascular density. Clin Cancer Res 1999; 5: 155-161.
20. Seki N, Kodama J, Hashimoto I Hongo A, Yoshinouchi M, Kudo T. Thrombospondin-1 and -2 messenger RNA expression in normal and neoplastic endometrial tissues: correlation with angiogenesis and prognosis. Int J Oncol 2001; 19: 305-310.
21. Salvesen HB, Akslen LA. Significance of tumour-associated macrophages, vascular endothelial growth factor and Thrombospondin- 1 expression for tumour angiogenesis and prognosis in endometrial carcinomas. Int J Cancer 1999; 84: 538-543.
22. Li Q, Ahuja N, Burger PC et al. Methylation and silencing of the Thrombospondin-1 promoter in human cancer. Oncogene 1999; 18: 3284-3289.
23. Jones, PA, Laird PW. Cancer epigenetics comes of age. Nat Genet 1999; 21: 163-167.
24. Strathdee G, Appleton K, Illand M et al. Primary ovarian carcinomas display multiple methylator phenotypes involving know tumor suppressor genes. Am J Pathol 2001; 158: 1121-1127.
25. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 1999; 96: 8681-8686.
26. Oue N, Matsumura S, Nakayama H et al. Reduced expression of the TSP1 gene and its association with promoter hypermethylation in gastric carcinoma. Oncology 2003; 64: 423-429.
27. Whitcomb BP, Mutch DG, Herzog TJ, Rader JS, Gibb RK, Goodfellow PJ. Frequent HOXA11 and THBS2 promoter methylation, and a methylator phenotype in endometrial adenocarcinoma. Clin Cancer Res 2003; 9: 2277-2287.
28. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996; 93: 9821-9826.
29. Weidner N. Tumor angiogenesis: review of current applications in tumor prognostication. Semin Diagn Pathol 1993; 10: 302-313
30. Kyriakides TR, Zhu YH, Smith LT et al. Mice that lack thrombospondin 2 display connective tissue abnormalities that are associated with disordered collagen fibrillogenesis, an increased vascular density, and a bleeding diathesis. J Cell Biol 1998; 140: 419-430.
31. Kodama J, Hashimoto I, Seki N et al. Thrombospondin-1 and -2 messenger RNA expression in epithelial ovarian tumor. Anticancer Res 2001; 21: 2983-2987.
32. Alvarez AA, Axelrod JR, Whitaker RS et al. Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients. Gynecol Oncol 2001; 82: 273-278.
33. Qian X, Rothman VL, Nicosia RF, Tuszynski GP. Expression of thrombospondin-1 in human pancreatic adenocarcinomas: role in matrix metalloproteinase-9 production. Pathol Oncol Res 2001; 7: 251-259.
34. Bornstein P, Kyriakides TR, Yang Z, Armstrong LC, Birk DE. Thrombospondin 2 modulates collagen fibrillogenesis and angiogenesis. J Investig Dermatol Symp Proc 2000; 5: 61-66.
35. Kasper HU, Ebert M, Malfertheiner P, Roessner A, Kirkpatrick CJ, Wolf HK. Expression of thrombospondin-1 in pancreatic carcinoma: correlation with microvessel density. Virchows Arch 2001; 438: 116-120.
36. Ichikawa Y, Yoshida S, Koyama Y et al. Inactivation of p16/CDKN2 and p15/MTS2 genes in different histological types and clinical stages of primary ovarian tumors. Int J Cancer 1996; 69: 466-470.
37. McCluskey LL, Chen C, Delgadillo E, Felix JC, Muderspach LI, Dubeau L. Differences in p16 gene methylation and expression in benign and malignant ovarian tumors. Gynecol Oncol 1999; 72: 87-92.
38. Katsaros D, Cho W, Singal R et al. Methylation of tumor suppressor gene p16 and prognosis of epithelial ovarian cancer. Gynecol Oncol 2004; 94: 685-692.
39. Czekierdowski A, Czekierdowska S, Szymanski M, Wielgos M, Kaminski P, Kotarski J. Opioid-binding protein/cell adhesion molecule-like (OPCML) gene and promoter methylation status in women with ovarian cancer. Neuro Endocrinol Lett 2006; 27: 609-613.
40. Czekierdowski A, Czekierdowska S, Wielgos M et al. The role of CpG islands hypomethylation and abnormal expression of neuronal protein synuclein-gamma (SNCG) in ovarian cancer. Neuro Endocrinol Lett 2006; 27: 381-386.
41. Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 2000; 16: 168-174.
42. Adolph KW, Liska DJ, Bornstein P. Analysis of the promoter and transcription start sites of the human thrombospondin 2 gene (THBS2). Gene 1997; 193: 5-11.
43. Yang QW, Liu S, Tian Y et al. Methylation-associated silencing of the thrombospondin-1 gene in human neuroblastoma. Cancer Res 2003; 63: 6299-6310.